KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Raw Materials (2016 - 2019)

Pfizer (PFE) has disclosed Raw Materials for 11 consecutive years, with $560.0 million as the latest value for Q1 2019.

  • On a quarterly basis, Raw Materials fell 32.12% to $560.0 million in Q1 2019 year-over-year; TTM through Mar 2019 was $560.0 million, a 32.12% decrease, with the full-year FY2018 number at $546.0 million, down 30.71% from a year prior.
  • Raw Materials was $560.0 million for Q1 2019 at Pfizer, up from $546.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $950.0 million in Q3 2016 to a low of $475.0 million in Q1 2015.
  • A 5-year average of $754.1 million and a median of $809.0 million in 2016 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: surged 84.82% in 2016, then crashed 32.12% in 2019.
  • Pfizer's Raw Materials stood at $867.0 million in 2015, then fell by 8.54% to $793.0 million in 2016, then fell by 0.63% to $788.0 million in 2017, then crashed by 30.71% to $546.0 million in 2018, then rose by 2.56% to $560.0 million in 2019.
  • Per Business Quant, the three most recent readings for PFE's Raw Materials are $560.0 million (Q1 2019), $546.0 million (Q4 2018), and $839.0 million (Q3 2018).